P78 CAN PET STANDARD UPTAKE VARIABLE (SUV) PREDICT DISEASE PROGRESSION IN EARLY-STAGE NON-SMALL CELL LUNG CANCER (NSCLC)?

FJ Frost, GH Jones, J Greenwood, M Ledson, MJ Walshaw. Liverpool Heart and Chest Hospital, Liverpool, UK

10.1136/thoraxjnl-2014-206260.219

Introduction The correlation between SUV on PET-CT and prognosis in NSCLC has been the subject of much debate. We were interested in whether SUVmax values could be used to determine which cases of early stage (1–2) NSCLC were likely to progress.

Methods We reviewed all 93 histologically proven early stage NSCLCs seen at our tertiary centre over a one year period. We defined those with SUVmax in the upper quartile as the high SUV group and compared these with the remainder. Historical data were considered to allow subsequent outcomes to be established.

Results Median follow up was 772 days during which time there was a 17% mortality rate [all-cause median time to death 338 days]. The median SUVmax for the cohort was 10.1, and those in the upper quartile all had results over 15.0.

The high SUVmax group (n = 27) and low SUVmax group (n = 68) had similar baseline characteristics, received similar treatment regimens and there were no significant differences in tumour size between the groups. Disease progression and mortality were both significantly higher in those with SUVmax in the upper quartile, despite this group tending to have earlier disease (see Table 1).

Retrospective analysis using Youdin’s index suggested that the optimal threshold for predicting disease progression was not significantly different when cases with nodal involvement were excluded [SUVmax 15.0 vs 15.5].

Conclusions Our results suggest that SUVmax may indeed help identify those patients with early stage NSCLC at higher risk of progression. In our large cohort those with an SUVmax of >15 were over 3 times more likely to develop progressive disease than those with lower results and this was independent of tumour size or nodal involvement. Whether individuals in the higher-risk group would benefit from increased surveillance or adjuvant therapy remains to be established.

Clinical management of pulmonary infection

P79 BRONCHIECTASIS SEVERITY IN PRIMARY IMMUNODEFICIENCY - A TWO CENTRE STUDY

1AD Saleh, 1JR Hurst, 2J Davison, 3C Stroud, 6D Lowe, 5A De Soyza. 1University College London, London, UK; 2Freeman Hospital Adult Bronchiectasis Service, Newcastle, UK; 3Immunology Department Royal Victoria Infirmary, Newcastle, UK; 4Institute for Immunity and Transplantation, Royal Free Hospital, London, UK; 5Institute of Cellular Medicine, Newcastle University and Freeman Hospital Adult Bronchiectasis Service, Newcastle, UK

Introduction Up to 70% of patients with Primary Immunodeficiency syndromes such as Common Variable Immunodeficiency (CVID) have bronchiectasis. Within this population it is a major driver of morbidity.1

The Bronchiectasis Severity Index (BSI) is capable of accurately categorising non-cystic fibrosis bronchiectasis patients into three severity groups that predict risk of hospitalisation and mortality at one and four years.2 It consists of nine clinical parameters, and was derived and validated in a diverse international bronchiectasis population. Mild disease is defined as a BSI score of <4, moderate 5–8 and severe >9.

This study aims to assess the relative severity of bronchiectasis associated with primary immunodeficiency.

Methods 24 Patients from the Royal Free Hospital, London and 22 patients from the Freeman Hospital Newcastle were recruited. Age, body mass index, predicted FEV1, number of hospitalisations in the last 2 years, number of exacerbations in the last year, medical research council dyspnoea (MRCID) score, Pseudomonas and other pathogen colonisation status and number or lobes involved on CT chest were obtained to calculate the BSI. Statistical analysis was carried out using SPSS V11.

Results The 46 patients were 67.4% female with a mean age of 55.9. There were no significant differences in age, gender or disease severity between the two centres. The median BSI was 4 (i.e. mild disease).

56% of patients had mild disease, 21.7% were moderate and 21.7% severe bronchiectasis. These patients had markedly less severe disease than the mixed aetiology population of 603 patients used to derive the scoring tool.

Conclusion Patients with Primary Immunodeficiency associated bronchiectasis were younger with less severe disease compared to the BSI cohort population previously reported. This suggests good multidisciplinary care in Primary Immunodeficiency with earlier referral to respiratory specialists. It also correlates with our prior longitudinal data that FEV1 decline in immunodeficiency-related bronchiectasis is less rapid than other aetiologies.1

<table>
<thead>
<tr>
<th>Age</th>
<th>% female</th>
<th>Predicted FEV1%</th>
<th>Median PS</th>
<th>%treated with curative intent</th>
<th>Median Stage</th>
<th>Disease Progression*</th>
<th>All cause Mortality*</th>
</tr>
</thead>
<tbody>
<tr>
<td>High SUV† (n = 27)</td>
<td>70.5</td>
<td>50%</td>
<td>80.8%</td>
<td>1</td>
<td>80.5%</td>
<td>1b</td>
<td>40.7%</td>
</tr>
<tr>
<td>Low SUV†</td>
<td>70.8</td>
<td>53%</td>
<td>77.6%</td>
<td>1</td>
<td>92.3%</td>
<td>2a</td>
<td>13.2%</td>
</tr>
</tbody>
</table>

†Cut off SUVmax =15; *Denotes significant statistical difference p < 0.05.
REFERENCE

P80 CHARACTERISATION OF THE EQ-5D-5L AND EXERCISE PERFORMANCE IN BRONCHIECTASIS
SJ Greenwood, T Pemberton, LJ Grillo. Physiotherapy Department, The Royal Brompton and Harefield NHS Foundation Trust, London, UK

Introduction and objectives NHS England have been looking at using the EQ-5D-5L as a measure of health outcome across the NHS. It is a simple measure which patients complete at the start and end of treatment to evaluate quality and effectiveness of interventions. To date there is no evidence on its use in Bronchiectasis (Bx). Moreover, evaluation of exercise performance is also vital as this can be associated with increased dyspnoea, reduced lung function or increased malaise. Sit to stand (5STS) and six minute walk test (6MWT) can be used to evaluate exercise performance but there is limited guidance on responsiveness and feasibility in Bx. This abstract provides novel data for these outcome measures (OM) in Bx patients during a routine inpatient stay.

Methods 20 Bx inpatients (Male: Female 20:20, Median age: 63 (29–74) Median FEV1: 1.26 (0.51–2.9) were assessed. 6MWT, 5STS and EQ-5D-5L were completed on all patients during their initial and final assessment.

Results Median length of stay was 10 days. Data is presented as median difference and comparisons were made using Wilcoxon Signed Rank tests.

Conclusion The EQ-5D-5L improved but did not show a significant difference, moreover there is currently no reported MCID for this OM. Significant differences were seen in both the 6MWT and 5STS. The 5STS is quick and feasible to complete and therefore maybe more preferable to use than the 6MWT. More understanding is needed on the utility of the EQ-5D-5L in this population.